{"content":"<li class=\"n-box-item date-title\" data-end=\"1459223999\" data-start=\"1459137600\" data-txt=\"Sunday, December 22, 2019\">Monday, March 28, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3169870\" data-ts=\"1459208183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169870-trovagene-removes-ceo-cfo-for-cause-and-files-complaint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene removes CEO, CFO for cause and files complaint</a></h4><ul>   <li>Trovagene (<a href=\"https://seekingalpha.com/symbol/TROV\" title=\"TrovaGene, Inc.\">TROV</a> <font color=\"red\">-1.7%</font>) says it's terminated its chief executive officer and chief financial officer for cause.</li>    <li>The company's board fired CEO Antonius Schuh and CFO Stephen Zaniboni and has filed a court complaint that includes a charge of breach of fiduciary duty.</li>    <li>Shares are <font color=\"red\">down 2.2%</font> after hours.</li>    <li>Trovagene says the pair failed to present a \"lucrative corporate opportunity\" to the board and instead took the opportunity for personal benefit. The company's asking them to turn over their interests in the new therapeutics.</li>    <li>Chairman Thomas Adams is serving as interim CEO, effective immediately. He's been chairman since April 2009.</li>\n<li>\n<strong>Update</strong>: The company has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1213037/000110465916108148/a16-7474_1ex99d1.htm\" target=\"_blank\">complaint </a>in the Superior Court of State of California for the County of San Diego demanding that Dr. Schuh and Mr. Zaniboni turn over their interests in the new therapeutics to Trovagene.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169870\" data-linked=\"Trovagene removes CEO, CFO for cause and files complaint\" data-tweet=\"$TROV - Trovagene removes CEO, CFO for cause and files complaint https://seekingalpha.com/news/3169870-trovagene-removes-ceo-cfo-for-cause-and-files-complaint?source=tweet\" data-url=\"https://seekingalpha.com/news/3169870-trovagene-removes-ceo-cfo-for-cause-and-files-complaint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169867\" data-ts=\"1459205154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFFX\" target=\"_blank\">AFFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169867-rejected-origin-withdraws-17-share-offer-for-affymetrix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rejected Origin withdraws $17/share offer for Affymetrix</a></h4><ul>   <li>With Affymetrix (<a href=\"https://seekingalpha.com/symbol/AFFX\" title=\"Affymetrix, Inc.\">AFFX</a> <font color=\"red\">-5.6%</font>) <a href=\"https://seekingalpha.com/news/3169811-regulatory-financing-uncertainties-china-sinks-origins-bid-affymetrix-shares-6-percent\" target=\"_blank\">spurning its offer</a> in favor of an existing bid from Thermo Fisher, Origin Technologies -- the former Affymetrix execs trying to private the company -- has withdrawn its $17/share cash offer.</li>    <li>Affymetrix earlier said it would stick with a $14/share bid from Thermo Fisher (<a href=\"https://seekingalpha.com/symbol/TMO\" title=\"Thermo Fisher Scientific Inc.\">TMO</a> <font color=\"red\">-0.4%</font>), which it considered less risky overall in case of a financing failure.</li>    <li>\u201cWe disagree with Affymetrix\u2019 assessment of the perceived risks of our proposal,\" says Origin President Wei Zhou. \"It is an unfortunate outcome.\u201d</li>    <li>Origin said it received an \"unrealistic demand\" on Friday evening to put hundreds of millions of dollars in a U.S. escrow account by today. The company says it looks forward to work on genomics at Centrillion Technologies.</li>    <li>Affymetrix shareholders are set to vote Thursday on the Thermo Fisher offer.</li>    <li>After hours: <a href=\"https://seekingalpha.com/symbol/AFFX\" title=\"Affymetrix, Inc.\">AFFX</a> <font color=\"red\">-0.8%</font>; <a href=\"https://seekingalpha.com/symbol/TMO\" title=\"Thermo Fisher Scientific Inc.\">TMO</a> flat.</li>\n<li>\n<strong>Update</strong>: TMO <a href=\"http://www.businesswire.com/news/home/20160331006243/en/Thermo-Fisher-Scientific-Completes-Acquisition-Affymetrix-Approval\" target=\"_blank\">completed </a>its acquisition of Affymetrix on March 31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169867\" data-linked=\"Rejected Origin withdraws $17/share offer for Affymetrix\" data-tweet=\"$AFFX $AFFX $TMO - Rejected Origin withdraws $17/share offer for Affymetrix https://seekingalpha.com/news/3169867-rejected-origin-withdraws-17-share-offer-for-affymetrix?source=tweet\" data-url=\"https://seekingalpha.com/news/3169867-rejected-origin-withdraws-17-share-offer-for-affymetrix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169858\" data-ts=\"1459201421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169858-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd'>TNK</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a> <font color='green'>+1.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-11.1%</font>. <a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a> <font color='red'>-7.7%</font>. <a href='https://seekingalpha.com/symbol/MDVN' title='Medivation, Inc.'>MDVN</a> <font color='red'>-6.1%</font>. <a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a> <font color='red'>-4.1%</font>. <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='red'>-3.8%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3169858\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$TNK $ADMS $FINL - After Hours Gainers / Losers https://seekingalpha.com/news/3169858-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3169858-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169857\" data-ts=\"1459201214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169857-foot-locker-to-join-s-and-p-500\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker to join S&amp;P 500</a></h4><ul>\n<li>Foot Locker (NYSE:<a href=\"https://seekingalpha.com/symbol/FL\" title=\"Foot Locker, Inc.\">FL</a>) <font color=\"green\">+2.1%</font> AH on news the stock will join the S&amp;P 500 index after the close of trading on April 1, replacing Cameron International, which is being acquired by Schlumberger in a deal expected  to be completed on or about that date.</li>\n<li>Also, DCT Industrial Trust (NYSE:<a href=\"https://seekingalpha.com/symbol/DCT\" title=\"DCT Industrial Trust Inc.\">DCT</a>) will replace FL in the S&amp;P MidCap 400 after the close on April 1.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169857\" data-linked=\"Foot Locker to join S&amp;P 500\" data-tweet=\"$FL $FL $DCT - Foot Locker to join S&amp;P 500 https://seekingalpha.com/news/3169857-foot-locker-to-join-s-and-p-500?source=tweet\" data-url=\"https://seekingalpha.com/news/3169857-foot-locker-to-join-s-and-p-500\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169849\" data-ts=\"1459199395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169849-warner-scores-lions-gate-fades-box-office\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Warner scores, Lions Gate fades at box office</a></h4><ul>   <li>It was a tale of two fortunes at the box office over a U.S. holiday weekend, with Warner Bros. reaping the benefits of a long-awaited superhero launch.</li>    <li>Time Warner (NYSE:<a href=\"https://seekingalpha.com/symbol/TWX\" title=\"Time Warner Inc.\">TWX</a>) <font color=\"green\">rose 3.6%</font> today as a critically panned <i>Batman v Superman: Dawn of Justice</i> still rolled to a $166.1M domestic gross and more than $424M globally. That's almost Warner's biggest domestic opening -- final numbers put it just behind <em>Harry Potter and the Deathly Hallows Part 2</em> -- and the biggest domestic opening weekend ever in March (passing <i>The Hunger Games'</i> $152.5M).</li>    <li>The film's having no trouble selling tickets despite negative reviews: Aggregator Rotten Tomatoes still has the film about 29% positive reaction, and it's drawn an (audience-based) CinemaScore of a flat B -- with a B-minus coming form the males that are making up 62% of the film's clientele.</li>    <li>Meanwhile, <i>Hunger Games</i> studio Lions Gate Entertainment (<a href=\"https://seekingalpha.com/symbol/LGF\" target=\"_blank\">LGF</a> <font color=\"green\">+1.6%</font>) rose today despite a serious drop-off in receipts for its <i>The Divergent Series: Allegiant,</i> which drew just $9.5M in its second week ($46.6M cumulative). The film's proving a letdown, and there's still another sequel in that series, <i>Ascendant,</i> yet to come in summer 2017.</li>    <li>Behind the dueling heroes, <i>Zootopia</i> (<a href=\"https://seekingalpha.com/symbol/DIS\" title=\"The Walt Disney Company\">DIS</a> <font color=\"green\">+0.9%</font>) took second with $23.1M, bringing its domestic total to $240.5M, and a counterprogrammed <i>My Big Fat Greek Wedding 2</i> (<a href=\"https://seekingalpha.com/symbol/CMCSA\" title=\"Comcast Corporation\">CMCSA</a> <font color=\"green\">+0.1%</font>) logged $18.1M for the No. 3 spot.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169661-imax-scores-big-batman-vs-superman-opening\" target=\"_blank\">IMAX scores big from Batman vs. Superman opening</a> (Mar. 28 2016)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169634-batman-v-superman-nails-box-office-record\" target=\"_blank\">'Batman v Superman' nails box office record</a> (Mar. 28 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169849\" data-linked=\"Warner scores, Lions Gate fades at box office\" data-tweet=\"$TWX $TWX $LGF.A - Warner scores, Lions Gate fades at box office https://seekingalpha.com/news/3169849-warner-scores-lions-gate-fades-box-office?source=tweet\" data-url=\"https://seekingalpha.com/news/3169849-warner-scores-lions-gate-fades-box-office\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169841\" data-ts=\"1459198308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169841-puma-bio-extends-neratinib-nda-filing-date-to-mid-year-shares-down-12-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Bio extends neratinib NDA filing date to mid-year; shares down 12% after hours</a></h4><ul>\n<li>Based on FDA feedback during recent meetings, Puma Biotechnology (NYSE:<a href=\"https://seekingalpha.com/symbol/PBYI\" title=\"Puma Biotechnology, Inc.\">PBYI</a>) pushes its projected filing date for its New Drug Application (NDA) seeking clearance of lead product candidate neratinib for the treatment of extended adjuvant breast cancer out until mid-2016 in order to accommodate FDA-requested changes.</li>\n<li>Specifically, the FDA wants the company to amend the statistical analysis plan for the Phase 3 ExteNET study to update the rules for censoring data for recurrent disease events or death. For the primary endpoint, invasive disease-free survival (iDFS), the original analysis was based on all recurrent disease events and deaths occurring with two years and 28 days after randomization. The new plan will censor the last available disease assessment time prior to the event occurrence in those cases where two or more disease assessment times were missed. This will be the primary analysis approach used in the efficacy analysis of the trial.</li>\n<li>The updated statistical approach will not affect the prior data in a material way. In the original analysis, the iDFS rates for neratinib and placebo were 93.9% and 91.6%, respectively. Under the new scheme, the numbers are 94.2% and 91.9%, respectively.</li>\n<li>The company cites a relative risk reduction of iDFA of 33% in the original analysis which increased to 34% when updated. This doesn't appear to mean much since neratinib failed to distance itself from placebo to a statistically valid degree.</li>\n<li>Shares are down <font color=\"red\">12%</font> after hours on increased volume.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/2979756-puma-bio-slumps-18-percent-still-underwhelming-late-stage-breast-cancer-trial-data-lead\" target=\"_blank\">Puma Bio slumps 18% on (still underwhelming) late-stage breast cancer trial data for lead product candidate</a> (Dec. 11, 2015)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169841\" data-linked=\"Puma Bio extends neratinib NDA filing date to mid-year; shares down 12% after hours\" data-tweet=\"$PBYI - Puma Bio extends neratinib NDA filing date to mid-year; shares down 12% after hours https://seekingalpha.com/news/3169841-puma-bio-extends-neratinib-nda-filing-date-to-mid-year-shares-down-12-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3169841-puma-bio-extends-neratinib-nda-filing-date-to-mid-year-shares-down-12-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169828\" data-ts=\"1459196459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169828-biopharmx-to-execute-secondary-equity-offering-shares-down-18-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX to execute secondary equity offering; shares down 18% after hours</a></h4><ul><li>BioPharmX (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/BPMX\" title=\"BioPharmX Corporation\">BPMX</a>) initiates a public offering of stock and warrants. Price, volume and terms have yet to be announced. Shares are off <font color=\"red\">18%</font> after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3169828\" data-linked=\"BioPharmX to execute secondary equity offering; shares down 18% after hours\" data-tweet=\"$BPMX - BioPharmX to execute secondary equity offering; shares down 18% after hours https://seekingalpha.com/news/3169828-biopharmx-to-execute-secondary-equity-offering-shares-down-18-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3169828-biopharmx-to-execute-secondary-equity-offering-shares-down-18-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169811\" data-ts=\"1459195975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFFX\" target=\"_blank\">AFFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169811-regulatory-and-financing-uncertainties-in-china-sinks-origins-bid-for-affymetrix-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulatory and financing uncertainties in China sinks Origin&#39;s bid for Affymetrix; shares down 6%</a></h4><ul>\n<li>Affymetrix (<a href=\"https://seekingalpha.com/symbol/AFFX\" title=\"Affymetrix, Inc.\">AFFX</a> <font color=\"red\">-5.5%</font>) retreats on more that quadruple normal volume in response to its announcement that the board has determined that Origin Technologies' $17-per-share unsolicited offer the company is not superior to Thermo Fisher's $14 bid.</li>\n<li>Prominent among the items that scuppered Origin's bid was the reverse termination fee of $100M, the maximum amount of recovery available to Affymetrix if Origin cannot obtain financing, a significant risk in its view. In addition, the fee would not be payable if Origin's financing was blocked by Chinese regulators, namely the Committee on Foreign Investment in the United States (CFIUS).</li>\n<li>In the board's opinion, Thermo's solid $1.5B bid is superior to Origin's which, in the worst case scenario, would pay nothing if financing failed and Thermo withdrew its offer.</li>\n<li>The Special Meeting of Stockholders will take place on March 31 during which AFFX shareholders will vote on the Thermo offer.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169060-origin-hikes-affymetrix-buyout-offer-17-share\" target=\"_blank\">Origin hikes Affymetrix buyout offer to $17/share</a> (March 22)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169811\" data-linked=\"Regulatory and financing uncertainties in China sinks Origin&#39;s bid for Affymetrix; shares down 6%\" data-tweet=\"$AFFX - Regulatory and financing uncertainties in China sinks Origin&#39;s bid for Affymetrix; shares down 6% https://seekingalpha.com/news/3169811-regulatory-and-financing-uncertainties-in-china-sinks-origins-bid-for-affymetrix-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3169811-regulatory-and-financing-uncertainties-in-china-sinks-origins-bid-for-affymetrix-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169820\" data-ts=\"1459195844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BX\" target=\"_blank\">BX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169820-pjt-partners-tumbles-on-charges-against-former-blackstone-executive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PJT Partners tumbles on charges against former Blackstone executive</a></h4><ul>\n<li>Former Blackstone Group (<a href=\"https://seekingalpha.com/symbol/BX\" title=\"The Blackstone Group L.P.\">BX</a> <font color=\"red\">-0.5%</font>) managing principal, and most recently an executive at spinoff Park Hill Group - now a part of PJT Partners (<a href=\"https://seekingalpha.com/symbol/PJT\" title=\"PJT Partners Inc.\">PJT</a> <font color=\"red\">-10.5%</font>) - Andrew Caspersen <a href=\"http://www.wsj.com/articles/prosecutors-charge-park-hill-managing-principal-in-investment-fraud-1459180880\" target=\"_blank\">has been charged</a> with stealing $25M from investors and scheming to defraud them of another $70M.</li>\n<li>The scion of a wealthy and powerful family, and graduate of Princeton and Harvard Law, allegedly solicited monies from a charitable institution, and instead of investing it as promised, blew it on options trading for his own account.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169820\" data-linked=\"PJT Partners tumbles on charges against former Blackstone executive\" data-tweet=\"$BX $BX $PJT - PJT Partners tumbles on charges against former Blackstone executive https://seekingalpha.com/news/3169820-pjt-partners-tumbles-on-charges-against-former-blackstone-executive?source=tweet\" data-url=\"https://seekingalpha.com/news/3169820-pjt-partners-tumbles-on-charges-against-former-blackstone-executive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169805\" data-ts=\"1459192127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VA\" target=\"_blank\">VA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169805-virgin-america-reportedly-offers-in-from-jblu-and-alk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Virgin America reportedly has offers in from JBLU and ALK</a></h4><ul> <li>Virgin America (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VA\" title=\"Virgin America\">VA</a>) received <a href=\"http://www.bloomberg.com/news/articles/2016-03-28/virgin-america-attracts-bids-from-jetblue-and-alaska-air\" target=\"_blank\">buyout offers</a> from JetBlue (<a href=\"https://seekingalpha.com/symbol/JBLU\" title=\"JetBlue Airways Corporation\">JBLU</a> <font color=\"green\">+3%</font>) and Alaska Air Group (<a href=\"https://seekingalpha.com/symbol/ALK\" title=\"Alaska Air Group, Inc.\">ALK</a> <font color=\"green\">+1.2%</font>), sources tip Bloomberg.</li> <li>The company is still talking to both of the bidders.</li> <li>A deal announcement could come as soon as next week.</li> <li>VA is <font color=\"green\">up 9.47%</font> to $37.40 off the latest devlopment. Some airline sector watchers think it would take an offer in the $40s to win Virgin.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169783-virgin-america-flies-higher-amid-buyout-talk\" target=\"_blank\">Virgin America flies higher amid buyout talk</a> (March 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169805\" data-linked=\"Virgin America reportedly has offers in from JBLU and ALK\" data-tweet=\"$VA $VA $JBLU - Virgin America reportedly has offers in from JBLU and ALK https://seekingalpha.com/news/3169805-virgin-america-reportedly-offers-in-from-jblu-and-alk?source=tweet\" data-url=\"https://seekingalpha.com/news/3169805-virgin-america-reportedly-offers-in-from-jblu-and-alk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169797\" data-ts=\"1459189868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SES\" target=\"_blank\">SES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169797-synthesis-energyplus-33-on-china-joint-development-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synthesis Energy +33% on China joint development deal</a></h4><ul>     <li>Synthesis Energy (SYMX <font color=\"green\">+33.1%</font>) shoots higher on news of a joint project development and investment agreement with China Environment State Investment Co. for at least 20 separate projects over the next five years using its SES gasification technology.</li>\n<li>SYMX says four target projects will focus initially on an industrial fuel syngas  project in Inner Mongolia for an  industrial park, an industrial hydrogen and fuel syngas project in Shandong province, and two industrial park syngas projects in Shandong and Hebei  provinces; the projects vary in size, and estimated costs of the four projects range at $75M-$400M per project.</li>     <li>SYMX will have a 49% stake in the joint venture.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169797\" data-linked=\"Synthesis Energy +33% on China joint development deal\" data-tweet=\"$SES - Synthesis Energy +33% on China joint development deal https://seekingalpha.com/news/3169797-synthesis-energyplus-33-on-china-joint-development-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3169797-synthesis-energyplus-33-on-china-joint-development-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169864\" data-ts=\"1459185610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTI\" target=\"_blank\">WTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169864-w-and-t-offshores-borrowing-base-cut-57-to-150m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W&amp;T Offshore&#39;s borrowing base cut 57% to $150M</a></h4><ul>     <li>W&amp;T Offshore (<a href=\"https://seekingalpha.com/symbol/WTI\" title=\"W&amp;T Offshore, Inc.\">WTI</a> <font color=\"red\">-4.6%</font>) faces a financial crunch after a lender  redetermination cut its borrowing base to $150M from $350M, the company announced after Thursday's close.</li>     <li>WTI says drew $340M on its revolving bank  credit facility during February and now has borrowings of $191M in excess of the redetermined borrowing base.</li>     <li>Stone Energy (SGY <font color=\"red\">-13.6%</font>), another company that has drawn down most of the amount remaining under its credit facility, also is lower after the U.S. Bureau of Energy Management determined that SGY <a href=\"https://biz.yahoo.com/e/160324/sgy8-k.html\" target=\"_blank\">no longer qualifies</a> for a supplemental bonding waiver.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169864\" data-linked=\"W&amp;T Offshore&#39;s borrowing base cut 57% to $150M\" data-tweet=\"$WTI $WTI $TALO - W&amp;T Offshore&#39;s borrowing base cut 57% to $150M https://seekingalpha.com/news/3169864-w-and-t-offshores-borrowing-base-cut-57-to-150m?source=tweet\" data-url=\"https://seekingalpha.com/news/3169864-w-and-t-offshores-borrowing-base-cut-57-to-150m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169787\" data-ts=\"1459184872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169787-big-reversal-for-gamestop-amid-talk-of-new-high-end-playstation-4-console\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big reversal for GameStop amid talk of new high-end PlayStation 4 console</a></h4><ul> <li>GameStop (<a href=\"https://seekingalpha.com/symbol/GME\" title=\"GameStop Corp.\">GME</a> <font color=\"green\">+0.9%</font>) is now in positive territory after an early round of post-earnings selling.</li> <li>A new <a href=\"http://www.wsj.com/articles/sony-plans-new-playstation-for-graphics-heavy-games-1459152941\" target=\"_blank\">WSJ report</a> indicating that Sony is planning on introducing a new high-end PlayStation 4 could be helping to bring in some buyers.</li> <li>Existing PlayStation 4 owners would need to buy a new console to take advantage of all the high-end graphics and virtual reality components, according to sources.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169686-gamestop-minus-7-percent-weak-guidance-creates-concerns\" target=\"_blank\">GameStop -7% as weak guidance creates concerns</a> (March 28)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169534-gamestop-falls-mixed-results-soft-guidance\" target=\"_blank\">GameStop falls after mixed results, soft guidance</a> (March 24)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3169787\" data-linked=\"Big reversal for GameStop amid talk of new high-end PlayStation 4 console\" data-tweet=\"$GME - Big reversal for GameStop amid talk of new high-end PlayStation 4 console https://seekingalpha.com/news/3169787-big-reversal-for-gamestop-amid-talk-of-new-high-end-playstation-4-console?source=tweet\" data-url=\"https://seekingalpha.com/news/3169787-big-reversal-for-gamestop-amid-talk-of-new-high-end-playstation-4-console\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169783\" data-ts=\"1459184300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VA\" target=\"_blank\">VA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169783-virgin-america-flies-higher-amid-buyout-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Virgin America flies higher amid buyout talk</a></h4><ul> <li>Virgin America (<a href=\"https://seekingalpha.com/symbol/VA\" title=\"Virgin America\">VA</a> <font color=\"green\">+3.6%</font>) trades at its highest level of the year as the guessing game continues over which airline company may try to buy out the budget carrier.</li> <li>Cowen says JetBlue (NASDAQ:<a href=\"https://seekingalpha.com/symbol/JBLU\" title=\"JetBlue Airways Corporation\">JBLU</a>) is the most likely acquirer of Virgin America, although Alaska Air Group (NYSE:<a href=\"https://seekingalpha.com/symbol/ALK\" title=\"Alaska Air Group, Inc.\">ALK</a>), Delta Air Lines (NYSE:<a href=\"https://seekingalpha.com/symbol/DAL\" title=\"Delta Air Lines, Inc.\">DAL</a>), and Hawaiian Holdings (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HA\" title=\"Hawaiian Holdings, Inc.\">HA</a>) could all be in the mix.</li> <li>Last week, Frank Holmes, CEO of the U.S. Global Jets ETF (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/JETS\" title=\"U.S. Global Jets ETF\">JETS</a>), <a href=\"http://www.benzinga.com/trading-ideas/long-ideas/16/03/7751460/southwest-not-united-could-buy-virgin-america-says-worlds-onl\" target=\"_blank\">noted</a> that Southwest Airlines (NYSE:<a href=\"https://seekingalpha.com/symbol/LUV\" title=\"Southwest Airlines Co.\">LUV</a>) is a natural fit in terms of culture and global opportunities. Many airline insiders think bidding action could take Virgin America's share price into the $40s.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169204-virgin-america-jumps-12-percent-report-takeover-interest\" target=\"_blank\">Virgin America jumps 12% on report of takeover interest</a> (March 23)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3169783\" data-linked=\"Virgin America flies higher amid buyout talk\" data-tweet=\"$VA $VA $JBLU - Virgin America flies higher amid buyout talk https://seekingalpha.com/news/3169783-virgin-america-flies-higher-amid-buyout-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3169783-virgin-america-flies-higher-amid-buyout-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169779\" data-ts=\"1459183658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169779-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers/ Losers</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/ALDR\" title=\"Alder Biopharmaceuticals Inc.\">ALDR</a> <font color=\"green\">+42%</font>. <a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a> <font color=\"green\">+22%</font>. <a href=\"https://seekingalpha.com/symbol/CDRB\" title=\"Code Rebel Corp\">CDRB</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/SKY\" title=\"Skyline Champion Corp\">SKY</a> <font color=\"green\">+17%</font>. SUNE <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/FINL\" title=\"The Finish Line, Inc.\">FINL</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/EDGE\" title=\"Edge Therapeutics\">EDGE</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/CLUB\" title=\"Town Sports International Holdings, Inc.\">CLUB</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/MNOV\" title=\"MediciNova, Inc.\">MNOV</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/DLHC\" title=\"DLH Holdings Corp\">DLHC</a> <font color=\"green\">+11%</font>.</li>\n<li>\n<b>Losers:</b> APRI <font color=\"red\">-48%</font>. <a href=\"https://seekingalpha.com/symbol/MNKD\" title=\"MannKind Corporation\">MNKD</a> <font color=\"red\">-22%</font>. <a href=\"https://seekingalpha.com/symbol/PTI\" title=\"Proteostasis Therapeutics\">PTI</a> <font color=\"red\">-15%</font>. <a href=\"https://seekingalpha.com/symbol/SXE\" title=\"Southcross Energy Partners\">SXE</a> <font color=\"red\">-13%</font>. SGY <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/PJT\" title=\"PJT Partners Inc.\">PJT</a> <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/PYDS\" title=\"Payment Data Systems, Inc.\">PYDS</a> <font color=\"red\">-12%</font>. PRGN <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/WSCI\" title=\"WSI Industries Inc.\">WSCI</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/CHNR\" title=\"China Natural Resources, Inc.\">CHNR</a> <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169779\" data-linked=\"Midday Gainers/ Losers\" data-tweet=\"$ALDR $ACAD $CDRB - Midday Gainers/ Losers https://seekingalpha.com/news/3169779-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3169779-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169775\" data-ts=\"1459182892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169775-valeant-chief-person-subpoenaed-to-testify-senate-committee-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant chief Person subpoenaed to testify before Senate committee; shares down 8%</a></h4><ul>\n<li>Valeant Pharmaceuticals (VRX <font color=\"red\">-7.8%</font>) slumps on increased volume in response to the <a href=\"http://www.reuters.com/article/us-valeant-senate-idUSKCN0WU1BZ\" target=\"_blank\">news</a> that CEO Michael Pearson has been subpoenaed to testify before the Senate Special Committee on Aging on April 27. The committee is one of two investigating aggressive drug pricing.</li>\n<li>Hopefully, the committee will get more cooperation from Mr. Pearson than the House Committee on Oversight and Government Reform did with Martin Shkreli in February.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169775\" data-linked=\"Valeant chief Person subpoenaed to testify before Senate committee; shares down 8%\" data-tweet=\"$BHC - Valeant chief Person subpoenaed to testify before Senate committee; shares down 8% https://seekingalpha.com/news/3169775-valeant-chief-person-subpoenaed-to-testify-senate-committee-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3169775-valeant-chief-person-subpoenaed-to-testify-senate-committee-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169786\" data-ts=\"1459181569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPI-OLD\" target=\"_blank\">SPI-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169786-spi-energy-s-chairman-becomes-ceo-amid-management-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPI Energy\u2019s Chairman becomes CEO amid management changes</a></h4><ul>     <li>SPI Energy (<a href=\"https://seekingalpha.com/symbol/SPI-OLD\" title=\"Scottish Power plc\">SPI-OLD</a> <font color=\"red\">-4.5%</font>) appoints Chairman Xiaofeng Peng as its new CEO after the current CEO and CFO stepped down from their positions.</li>     <li>Roger Dejun Ye will remain with SPI as an executive VP in charge of the solar business and is appointed to the company\u2019s board.</li>     <li>CFO Amy Jing Liu resigns from her position and leaves the board and the company; Tairan Guo, who had led SPI\u2019s green energy payment platform, is named interim CFO.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169786\" data-linked=\"SPI Energy\u2019s Chairman becomes CEO amid management changes\" data-tweet=\"$SPI-OLD - SPI Energy\u2019s Chairman becomes CEO amid management changes https://seekingalpha.com/news/3169786-spi-energy-s-chairman-becomes-ceo-amid-management-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/3169786-spi-energy-s-chairman-becomes-ceo-amid-management-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169768\" data-ts=\"1459181067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNOV\" target=\"_blank\">MNOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169768-medicinova-awarded-patent-in-china-covering-mnminus-001-shares-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediciNova awarded patent in China covering MN-001; shares up 15%</a></h4><ul>\n<li>Thinly traded micro cap MediciNova (<a href=\"https://seekingalpha.com/symbol/MNOV\" title=\"MediciNova, Inc.\">MNOV</a> <font color=\"green\">+14.9%</font>) is up on a 50% spike in volume in apparent response to its announcement that it has received a Notice of Allowance from the Chinese Patent Office for a patent covering MN-001 (tipelukast).</li>\n<li>\n<a href=\"http://medicinova.com/clinical-development/core/mn-001-nash/\" target=\"_blank\">Tipelukast </a>is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase. It is under development for the treatment of NASH (nonalcoholic steatohepatitis) patients with elevated triglycerides and moderate-to-severe ideopathic pulmonary fibrosis. Both are unmet medical needs in China.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169768\" data-linked=\"MediciNova awarded patent in China covering MN-001; shares up 15%\" data-tweet=\"$MNOV - MediciNova awarded patent in China covering MN-001; shares up 15% https://seekingalpha.com/news/3169768-medicinova-awarded-patent-in-china-covering-mnminus-001-shares-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3169768-medicinova-awarded-patent-in-china-covering-mnminus-001-shares-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169760\" data-ts=\"1459178431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEEL\" target=\"_blank\">SEEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169760-apricus-bios-fispemifene-flunks-mid-stage-study-shares-down-51\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apricus Bio&#39;s fispemifene flunks mid-stage study; shares down 51%</a></h4><ul>\n<li>Thinly traded nano cap Apricus Biosciences (APRI <font color=\"red\">-50.6%</font>) slumps on an 8x surge in volume in response to its announcement that its candidate for the treatment of men with secondary hypogonadism, <a href=\"http://www.apricusbio.com/pipeline/fispemifene/\" target=\"_blank\">fispemifene</a>, failed to achieve its primary endpoint in a Phase 2b clinical trial.</li>\n<li>The primary objective of the 160-subject study was to assess fispemifene's ability to improve sexual function in men with low testosterone. Participants treated with the 450 mg dose showed a statistically valid increase in total, percent free and percent bioavailable testosterone versus placebo (p&lt;0.0001 at weeks 4 and 8), but the magnitude of the increase was not enough to achieve statistical significance for either the erectile function primary endpoint or low libido secondary endpoint.</li>\n<li>CEO Richard Pascoe says, \"We are obviously disappointed with these results. As as consequence of these results, we will discontinue all development of fispemifene in symptomatic secondary hypogonadism and focus our resources on our homegrown pipeline assets [Vitaros, RayVa].</li>\n<li>\n<a href=\"http://www.apricusbio.com/pipeline/fispemifene/\" target=\"_blank\">Fispemifene </a>is an estrogen receptor modulator that increases testosterone production in the testes via an estrogen-blocking effect in the pituitary gland.</li>\n<li>\n<strong>Update</strong>: In an <a href=\"https://www.sec.gov/Archives/edgar/data/1017491/000101749116000132/a8-kapril62016.htm\" target=\"_blank\">8-K filed on April 6</a>, the company reported that it will implement a restructuring plan that will reduce operating costs and headcount 30%. The workforce reduction should be completed by the end of Q3. It expects to book ~$1M in charges related to the initiative.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169760\" data-linked=\"Apricus Bio&#39;s fispemifene flunks mid-stage study; shares down 51%\" data-tweet=\"$SEEL - Apricus Bio&#39;s fispemifene flunks mid-stage study; shares down 51% https://seekingalpha.com/news/3169760-apricus-bios-fispemifene-flunks-mid-stage-study-shares-down-51?source=tweet\" data-url=\"https://seekingalpha.com/news/3169760-apricus-bios-fispemifene-flunks-mid-stage-study-shares-down-51\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169754\" data-ts=\"1459177109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169754-petrobras-bond-yields-tumbled-since-january-amid-stronger-currency\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras bond yields have tumbled since January amid stronger currency</a></h4><ul>     <li>Petrobras (<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a> <font color=\"green\">+4.5%</font>) appears to have become <a href=\"http://www.bloomberg.com/news/articles/2016-03-28/petrobras-bondholders-see-rare-bright-spot-in-brazil-s-currency\" target=\"_blank\">less of a default risk</a> in the eyes of bondholders, thanks to the Brazilian real\u2019s 7.8% surge YTD vs. the U.S. dollar - the second-biggest gain in the world - which is helping the company\u2019s ability to repay dollar-denominated debt.</li>     <li>Bloomberg reports that yields on PBR\u2019s $1.6B of bonds due in March 2017 have plunged nearly six percentage points from a three-month high on Jan. 20, and now yield less than notes maturing in 2024, a reversal  of the inverted curve that prevailed just two months ago.</li>\n<li>Separately, PBR says it will hold a shareholder meeting on April 28 to <a href=\"http://www.reuters.com/article/us-petrobras-shareholders-idUSKCN0WU0X2\" target=\"_blank\">vote on proposed changes to its board</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169754\" data-linked=\"Petrobras bond yields have tumbled since January amid stronger currency\" data-tweet=\"$PBR - Petrobras bond yields have tumbled since January amid stronger currency https://seekingalpha.com/news/3169754-petrobras-bond-yields-tumbled-since-january-amid-stronger-currency?source=tweet\" data-url=\"https://seekingalpha.com/news/3169754-petrobras-bond-yields-tumbled-since-january-amid-stronger-currency\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169748\" data-ts=\"1459175669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAR\" target=\"_blank\">MAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169748-marriott-international-higher-after-anbang-ups-offer-for-starwood\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marriott International higher after Anbang ups offer for Starwood</a></h4><ul> <li>Shares of Marriott International (NYSE:<a href=\"https://seekingalpha.com/symbol/MAR\" title=\"Marriott International, Inc.\">MAR</a>) are <font color=\"green\">up 3.6%</font> off news that the company's offer for Starwood Hotels &amp; Resorts was topped by a consortium led by Anbang.</li> <li>Some Marriott investors seem to prefer that the company pass on the Starwood deal. As <a href=\"https://seekingalpha.com/article/3960229-anbang-re-enter-marriotts-deal-starwood\" target=\"_blank\">pointed out</a> by SA contributor J.G. Collins, a Starwood-Marriott merger could face some painful obstacles in China.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3169748\" data-linked=\"Marriott International higher after Anbang ups offer for Starwood\" data-tweet=\"$MAR - Marriott International higher after Anbang ups offer for Starwood https://seekingalpha.com/news/3169748-marriott-international-higher-after-anbang-ups-offer-for-starwood?source=tweet\" data-url=\"https://seekingalpha.com/news/3169748-marriott-international-higher-after-anbang-ups-offer-for-starwood\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169745\" data-ts=\"1459175619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JOY\" target=\"_blank\">JOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169745-jpmorgan-still-cautious-joy-global\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan still cautious about Joy Global</a></h4><ul>\n<li>JPMorgan\u2019s Ann Duignan and Michael Conlon <a href=\"http://blogs.barrons.com/stockstowatchtoday/2016/03/28/joy-global-we-remain-cautious-jpmorgan-says/?mod=yahoobarrons&amp;ru=yahoo\" target=\"_blank\">\"remain cautious\"</a> on Joy Global (<a href=\"https://seekingalpha.com/symbol/JOY\" title=\"Joy Global Inc.\">JOY</a> <font color=\"red\">-3.1%</font>) despite the stock's rally this year:</li>\n<li>\"We hosted a call with Joy's CFO, Jim Sullivan, to discuss the company\u2019s restructuring actions as well as a look back at the cycle. One of the key points of discussion included a comparison between FY\u201906 and FY\u201916E as sales were about the same but profits are expected to be significantly lower.\"</li>\n<li>\"Overall, the CFO noted that its customers have had a more optimistic tone of late, but there has been no real change in the trajectory of orders for JOY.\"</li>\n<li>\"We remain cautious as the stock has rallied YTD <font color=\"green\">+21%</font> (vs. the S&amp;P 500's <font color=\"red\">-0.4%</font>) while the fundamentals remain weak, especially in U.S. and China coal sectors.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169745\" data-linked=\"JPMorgan still cautious about Joy Global\" data-tweet=\"$JOY - JPMorgan still cautious about Joy Global https://seekingalpha.com/news/3169745-jpmorgan-still-cautious-joy-global?source=tweet\" data-url=\"https://seekingalpha.com/news/3169745-jpmorgan-still-cautious-joy-global\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169746\" data-ts=\"1459175608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TKR\" target=\"_blank\">TKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169746-timken-downgraded-to-neutral-from-buy-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Timken downgraded to Neutral from Buy at Goldman</a></h4><ul>     <li>Timken (<a href=\"https://seekingalpha.com/symbol/TKR\" title=\"Timken Co.\">TKR</a> <font color=\"red\">-2.1%</font>) is <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/03/7763179/goldman-sachs-downgrades-timken-to-neutral\" target=\"_blank\">downgraded</a> to Neutral from Buy with a $30 price target, lowered from $31, at Goldman Sachs, which says organic growth would need to accelerate to justify the stock\u2019s full valuation.</li>     <li>While shares have declined to come more in-line with the sector average, Goldman says this occurred as the company\u2019s fundamentals have weakened and will remain under pressure due to a limited recovery in industrial distribution and continued OEM headwinds; TKR is expected to generate a 5% organic decline in 2016.</li>     <li>Goldman also says TKR already has achieved its targeted re-leveraging of its balance sheet, thus further benefits from re-leveraging are unlikely.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169746\" data-linked=\"Timken downgraded to Neutral from Buy at Goldman\" data-tweet=\"$TKR - Timken downgraded to Neutral from Buy at Goldman https://seekingalpha.com/news/3169746-timken-downgraded-to-neutral-from-buy-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3169746-timken-downgraded-to-neutral-from-buy-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169741\" data-ts=\"1459175193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REV\" target=\"_blank\">REV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169741-revlon-investors-testy-over-new-ceo-hire\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revlon investors testy over new CEO hire</a></h4><ul> <li>Revlon (NYSE:<a href=\"https://seekingalpha.com/symbol/REV\" title=\"Revlon, Inc.\">REV</a>) names Fabian Garcia as its new CEO. The Colgate-Palmolive vet takes over the position on April 15.</li> <li>Investors are selling shares of Revlon off the news, presumably because it lowers the odds of a buyout.</li> <li>Revlon is <font color=\"red\">down 10.1%</font> on very heavy volume. The stock was up sharply after the CEO resignation was announced last month.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3169741\" data-linked=\"Revlon investors testy over new CEO hire\" data-tweet=\"$REV - Revlon investors testy over new CEO hire https://seekingalpha.com/news/3169741-revlon-investors-testy-over-new-ceo-hire?source=tweet\" data-url=\"https://seekingalpha.com/news/3169741-revlon-investors-testy-over-new-ceo-hire\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169740\" data-ts=\"1459174854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAC\" target=\"_blank\">MAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169740-macerich-lower-after-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macerich lower after downgrade</a></h4><ul>\n<li>An outlier to the downside among the mall operators today is Macerich (<a href=\"https://seekingalpha.com/symbol/MAC\" title=\"Macerich Co.\">MAC</a> <font color=\"red\">-0.8%</font>) after Bank of America pulls its Buy rating and downgrades to Neutral.</li>\n<li>BofA upgraded Macerich earlier this year, and the stock price is pretty much flat since (though it has gyrated a bit alongside the market).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169740\" data-linked=\"Macerich lower after downgrade\" data-tweet=\"$MAC - Macerich lower after downgrade https://seekingalpha.com/news/3169740-macerich-lower-after-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3169740-macerich-lower-after-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169739\" data-ts=\"1459174691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169739-finish-line-off-and-running-after-backing-from-wall-street-firms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line off and running after backing from Wall Street firms</a></h4><ul> <li>Finish Line (<a href=\"https://seekingalpha.com/symbol/FINL\" title=\"The Finish Line, Inc.\">FINL</a> <font color=\"green\">+9%</font>) races higher after it catches an upgrade from BB&amp;T. The investment firm moves to a Buy rating from Neutral.</li>  <li>Jefferies <a href=\"http://www.marketbeat.com/stocks/NASDAQ/FINL/\" target=\"_blank\">lifts</a> its price target on the retail stock to $24 and Canaccord Genuity backs its Buy rating.</li> <li>Finish Line reported earnings last Thursday.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169374-finish-line-beats-0_03-beats-revenue\" target=\"_blank\">Finish Line beats by $0.03, beats on revenue</a> (March 24)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169403-finish-lines-fq4\" target=\"_blank\">More on Finish Line's FQ4</a> (March 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169739\" data-linked=\"Finish Line off and running after backing from Wall Street firms\" data-tweet=\"$FINL - Finish Line off and running after backing from Wall Street firms https://seekingalpha.com/news/3169739-finish-line-off-and-running-after-backing-from-wall-street-firms?source=tweet\" data-url=\"https://seekingalpha.com/news/3169739-finish-line-off-and-running-after-backing-from-wall-street-firms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169738\" data-ts=\"1459174584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169738-cellcom-summoned-antitrust-regulator-mulls-300m-golan-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom summoned as antitrust regulator mulls $300M Golan deal</a></h4><ul>   <li>Cellcom Israel (<a href=\"https://seekingalpha.com/symbol/CEL\" title=\"Cellcom Israel, Ltd.\">CEL</a> <font color=\"green\">+2.1%</font>) says Israel's antitrust commissioner has told the company it may oppose its $300M deal to buy Golan Telecom.</li>    <li>The regulator has summoned Cellcom to a hearing to determine whether modifications can be made to address the current layout of the deal.</li>    <li>When the company <a href=\"https://seekingalpha.com/news/2898756-cellcom-israel-announces-300m-deal-buy-golan-telecom\" target=\"_blank\">announced the deal</a> in November, it was against the backdrop of mixed signals from Israel's government about consolidating the market. Ministry of Communications chief Shlomo Filber had said \"I don\u2019t see a problem with Cellcom, Partner or Bezeq buying Golan if they want ... The market will continue to be competitive even with four main players and other niche players.\"</li>    <li>That was followed by other ministers who stated they might opposed consolidation.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/2898756-cellcom-israel-announces-300m-deal-buy-golan-telecom\" target=\"_blank\">Cellcom Israel announces $300M deal to buy Golan Telecom</a> (Nov. 05 2015)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169738\" data-linked=\"Cellcom summoned as antitrust regulator mulls $300M Golan deal\" data-tweet=\"$CEL - Cellcom summoned as antitrust regulator mulls $300M Golan deal https://seekingalpha.com/news/3169738-cellcom-summoned-antitrust-regulator-mulls-300m-golan-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3169738-cellcom-summoned-antitrust-regulator-mulls-300m-golan-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169733\" data-ts=\"1459174145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ODP\" target=\"_blank\">ODP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169733-office-depot-and-staples-higher-amazon-defense-factors-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Office Depot and Staples higher as Amazon defense factors in</a></h4><ul> <li>Office Depot (NYSE:<a href=\"https://seekingalpha.com/symbol/ODP\" title=\"Office Depot Inc.\">ODP</a>) is <font color=\"green\">up 5.4%</font> in early trading on more enthusiasm over the stance of judge weighing the FTC's argument against the ODP-Staples merger.</li> <li>Staples (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SPLS\" title=\"Staples, Inc.\">SPLS</a>) is <font color=\"green\">1.9% higher</font> to follow on last week's late rally.</li>\n<li>As more of the courtroom back-and-forth has been revealed, it's become more apparent that the Amazon argument may play for Office Depot and Staples.</li> <li>\"The court exchange revealed pretty clear evidence that Amazon is, actually, well on its way to establishing a robust business in the space,\" <a href=\"http://www.retaildive.com/news/judge-takes-major-issue-with-ftc-in-staplesoffice-depot-proceedings/416354/\" target=\"_blank\">notes</a> RetailDive.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3169733\" data-linked=\"Office Depot and Staples higher as Amazon defense factors in\" data-tweet=\"$ODP $ODP $SPLS - Office Depot and Staples higher as Amazon defense factors in https://seekingalpha.com/news/3169733-office-depot-and-staples-higher-amazon-defense-factors-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3169733-office-depot-and-staples-higher-amazon-defense-factors-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169731\" data-ts=\"1459173672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBSH\" target=\"_blank\">UBSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169731-union-bankshares-higher-after-two-notch-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Bankshares higher after two-notch upgrade</a></h4><ul><li>Union First Market Bankshares (<a href=\"https://seekingalpha.com/symbol/UBSH\" title=\"Union Bankshares Corporation\">UBSH</a> <font color=\"green\">+3.6%</font>) is boosted all the way <a href=\"http://www.streetinsider.com/Hot+Upgrades/Raymond+James+Upgrades+Union+First+Market+Bankshares+%28UBSH%29+to+Strong+Buy/11450626.html\" target=\"_blank\">to Strong Buy</a> from Market Perform at Raymond James. The $28 price target is 21% above Thursdays' close.</li></ul><div class=\"tiny-share-widget\" data-id=\"3169731\" data-linked=\"Union Bankshares higher after two-notch upgrade\" data-tweet=\"$UBSH $AUB - Union Bankshares higher after two-notch upgrade https://seekingalpha.com/news/3169731-union-bankshares-higher-after-two-notch-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3169731-union-bankshares-higher-after-two-notch-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169726\" data-ts=\"1459172851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169726-you-on-demand-names-new-cfo-e-commerce-president\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">You On Demand names new CFO, e-commerce president</a></h4><ul>   <li>Video provider You On Demand (<a href=\"https://seekingalpha.com/symbol/YOD\" target=\"_blank\">YOD</a> <font color=\"green\">+2.8%</font>) has named Mei Chen its new chief financial officer, effective April 1.</li>    <li>In addition, Bing Yang is joining the firm to head up a newly formed E-Commerce division.</li>    <li>Chen joins the company most recently from Microsoft China, after years at multinationals including Cisco and Nokia. Yang, meanwhile, was most recently CEO of e-commerce firm KJT.</li>    <li>The company will discuss the hires and the new division on its Q4 earnings call, now moved from Wednesday morning to after the close Wednesday, at 4:30 p.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169726\" data-linked=\"You On Demand names new CFO, e-commerce president\" data-tweet=\"$SSC-OLD - You On Demand names new CFO, e-commerce president https://seekingalpha.com/news/3169726-you-on-demand-names-new-cfo-e-commerce-president?source=tweet\" data-url=\"https://seekingalpha.com/news/3169726-you-on-demand-names-new-cfo-e-commerce-president\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169725\" data-ts=\"1459172723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SXE\" target=\"_blank\">SXE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169725-southcross-energy-partners-parent-files-for-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southcross Energy Partners parent files for bankruptcy</a></h4><ul>     <li>Southcross Holdings LP, parent company of Southcross Energy Partners (<a href=\"https://seekingalpha.com/symbol/SXE\" title=\"Southcross Energy Partners\">SXE</a> <font color=\"red\">-4.7%</font>), confirms it filed a prepackaged chapter 11 plan after creditors voted to <a href=\"http://www.wsj.com/articles/southcross-energy-parent-files-for-bankruptcy-1459170171\" target=\"_blank\">approve the company\u2019s restructuring proposal</a>.</li>     <li>The plan calls for the holding company\u2019s owners to contribute up to $170M in return for two-thirds of the equity in the reorganized company; if approved, the plan is expected to result in the elimination of nearly $700M in debt.</li>     <li>Southcross Holdings owns 100% of Southcross Energy Partners GP, SXE's general partner; neither SXE nor the general partner are part of the holding company\u2019s bankruptcy filing.</li>     <li>\n<a href=\"https://seekingalpha.com/news/3168976-southcross-energy-partners-soars-part-parents-chapter-11-filing\" target=\"_blank\">Earlier</a>: Southcross Energy Partners soars; not part of parent's Chapter 11 filing (Mar. 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169725\" data-linked=\"Southcross Energy Partners parent files for bankruptcy\" data-tweet=\"$SXE $SXE-OLD - Southcross Energy Partners parent files for bankruptcy https://seekingalpha.com/news/3169725-southcross-energy-partners-parent-files-for-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3169725-southcross-energy-partners-parent-files-for-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169719\" data-ts=\"1459171831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAR\" target=\"_blank\">MAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169719-anbang-consortium-ups-offer-for-starwood-hotels-resorts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anbang consortium ups offer for Starwood Hotels &amp; Resorts</a></h4><ul> <li>Starwood Hotels &amp; Resorts (HOT) says a new offer from a consortium led by Anbang came in at $82.75 per share. If the consideration for Interval Leisure Group (IILG) is factored in, the offer has a combined value of $88.66.</li> <li>The company says the new bid is \"reasonably likely\" to qualify as a superior proposal, although Marriott International (NYSE:<a href=\"https://seekingalpha.com/symbol/MAR\" title=\"Marriott International, Inc.\">MAR</a>) can still come in with another offer. The Starwood board is on record as preferring the Marriott offer.</li> <li>HOT <font color=\"green\">+2.42%</font> premarket to $84.10.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3169719\" data-linked=\"Anbang consortium ups offer for Starwood Hotels &amp; Resorts\" data-tweet=\"$MAR $MAR $ILG - Anbang consortium ups offer for Starwood Hotels &amp; Resorts https://seekingalpha.com/news/3169719-anbang-consortium-ups-offer-for-starwood-hotels-resorts?source=tweet\" data-url=\"https://seekingalpha.com/news/3169719-anbang-consortium-ups-offer-for-starwood-hotels-resorts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169718\" data-ts=\"1459171691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBSN\" target=\"_blank\">GBSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169718-fda-clears-great-basins-multiplex-staph-blood-culture-panel-shares-up-43-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Great Basin&#39;s multiplex Staph Blood Culture Panel; shares up 43% premarket</a></h4><ul>\n<li>Nano cap Great Basin Scientific (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GBSN-OLD\" title=\"Great Basin Scientific, Inc.\">GBSN</a>) is up <font color=\"green\">43%</font> premarket on robust volume in response to its announcement that it has received 510(k) clearance from the FDA for its first DNA multiplex assay, the Staph ID/R Blood Culture Panel.</li>\n<li>The test, performed on the company's Great Basin Analyzer, is an automated assay for the simultaneous identification of Staphylococcus aureus and Staphylococcus species directly from positive blood cultures. Results are generated in ~two hours. The panel also detects the medA gene, a biomarker for resistance to methicillin and other beta-lactam antibiotics.</li>\n<li>The company intends to offer the panel at a significantly lower cost that other commercially available blood panels.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169718\" data-linked=\"FDA clears Great Basin&#39;s multiplex Staph Blood Culture Panel; shares up 43% premarket\" data-tweet=\"$GBSN $GBSN-OLD - FDA clears Great Basin&#39;s multiplex Staph Blood Culture Panel; shares up 43% premarket https://seekingalpha.com/news/3169718-fda-clears-great-basins-multiplex-staph-blood-culture-panel-shares-up-43-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3169718-fda-clears-great-basins-multiplex-staph-blood-culture-panel-shares-up-43-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169710\" data-ts=\"1459170925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169710-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul>\n<li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/ALDR\" title=\"Alder Biopharmaceuticals Inc.\">ALDR</a> <font color=\"green\">+26%</font>. <a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/LEU\" title=\"Centrus Energy Corp.\">LEU</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/ARLZ-OLD\" title=\"Aralez Pharmaceuticals Inc.\">ARLZ-OLD</a> <font color=\"green\">+10%</font>. SUNE <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/ITUB\" title=\"Itau Unibanco Holding S.A.\">ITUB</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/VCEL\" title=\"Vericel Corporation\">VCEL</a> <font color=\"green\">+5%</font>.</li>\n<li>\n<b>Losers:</b> APRI <font color=\"red\">-53%</font>. <a href=\"https://seekingalpha.com/symbol/VSCP\" title=\"VirtualScopics, Inc.\">VSCP</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/EGRX\" title=\"Eagle Pharmaceuticals Inc.\">EGRX</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/P\" title=\"Pandora Media\">P</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/GME\" title=\"GameStop Corp.\">GME</a> <font color=\"red\">-7%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169710\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$ALDR $ACAD $LEU - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3169710-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3169710-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169708\" data-ts=\"1459170539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169708-expected-fda-clearance-of-transenterixs-surgibot-pushed-out-to-april-shares-down-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Expected FDA clearance of TransEnterix&#39;s SurgiBot pushed out to April; shares down 10% premarket</a></h4><ul>\n<li>TransEnterix (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/TRXC\" title=\"TransEnterix, Inc.\">TRXC</a>) is down <font color=\"red\">10%</font> premarket on light volume in response to its announcement that it now expects to receive the FDA's decision on its 510(k) application for its robotic surgery system, SurgiBot, by mid-April. It had expected to receive notification in Q1.</li>\n<li>The review clock for a 510(k), a regulatory pathway with a lower bar for approval than a PMA (pre-market approval), is usually ~six months. The company submitted its application on or about June 1, 2015 so the agency's review is already tardy, increasing that risk that there could be deficiencies in the filing that could delay clearance.</li>\n<li>The single-port <a href=\"http://www.transenterix.com/technology/surgibot/\" target=\"_blank\">Surgibot </a>system allows the surgeon to be in the sterile field which means he/she can stand beside the patient rather than sit behind a console like Intuitive Surgical's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ISRG\" title=\"Intuitive Surgical, Inc.\">ISRG</a>) <em>da Vinci</em> system. It also features a combination of reusable and disposable instruments.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3095886-transenterix-moving-closer-launch-surgibot-system-shares-18-percent-premarket-profit-taking\" target=\"_blank\">TransEnterix moving closer to launch of SurgiBot System; shares down 18% premarket on profit taking</a> (Feb. 10)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169708\" data-linked=\"Expected FDA clearance of TransEnterix&#39;s SurgiBot pushed out to April; shares down 10% premarket\" data-tweet=\"$TRXC $TRXC $ISRG - Expected FDA clearance of TransEnterix&#39;s SurgiBot pushed out to April; shares down 10% premarket https://seekingalpha.com/news/3169708-expected-fda-clearance-of-transenterixs-surgibot-pushed-out-to-april-shares-down-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3169708-expected-fda-clearance-of-transenterixs-surgibot-pushed-out-to-april-shares-down-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169702\" data-ts=\"1459170265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEU\" target=\"_blank\">LEU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169702-centrus-signs-new-contract-for-american-centrifuge-work\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centrus signs new contract for American centrifuge work</a></h4><ul>\n<li>Centrus Energy (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/LEU\" title=\"Centrus Energy Corp.\">LEU</a>) <font color=\"green\">+11.7% </font>premarket after signing a new U.S. centrifuge technology advancement contract with  UT-Battelle, as operator of the U.S. Department of Energy's Oak Ridge National Laboratory.</li>\n<li>LEU says the agreement will allow it to continue to perform engineering and testing work to preserve and  advance U.S. uranium enrichment technology.</li>\n<li>The contract totals ~$32.3M and runs through Sept. 30.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169702\" data-linked=\"Centrus signs new contract for American centrifuge work\" data-tweet=\"$LEU - Centrus signs new contract for American centrifuge work https://seekingalpha.com/news/3169702-centrus-signs-new-contract-for-american-centrifuge-work?source=tweet\" data-url=\"https://seekingalpha.com/news/3169702-centrus-signs-new-contract-for-american-centrifuge-work\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169689\" data-ts=\"1459169260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARLZ-OLD\" target=\"_blank\">ARLZ-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169689-fda-accepts-aralez-pharmas-resubmitted-nda-for-yosprala-shares-up-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Aralez Pharma&#39;s resubmitted NDA for YOSPRALA; shares up 16% premarket</a></h4><ul>\n<li>Micro cap Aralez Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ARLZ-OLD\" title=\"Aralez Pharmaceuticals Inc.\">ARLZ-OLD</a>) is up <font color=\"green\">16%</font> premarket on modest volume in response to its announcement that the FDA has accepted for review its resubmitted New Drug Application (NDA) seeing clearance of YOSPRALA (aspirin + omeprazole) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA's action date (PDUFA) is September 14.</li>\n<li>The company received two earlier Complete Response Letters (CRLs), one in December 2014 and an earlier one in April 2014. The deficiencies pertained to the manufacturing facility of the then-aspirin supplier. The resubmission includes a new primary aspirin supplier in addition to an alternative supplier.</li>\n<li>\n<a href=\"http://aralez.com/Portfolio/yosprala/\" target=\"_blank\">YOSPRALA </a>is a combination of <a href=\"http://www.drugs.com/omeprazole.html\" target=\"_blank\">omeprazole</a>, a proton pump inhibitor that reduces stomach acid, and a PH-sensitive enteric coated aspirin.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3167534-aralez-resubmits-yosprala-nda-secondary-prevention-cv-disease-certain-patients\" target=\"_blank\">Aralez resubmits Yosprala NDA for secondary prevention of CV disease in certain patients</a> (March 15)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169689\" data-linked=\"FDA accepts Aralez Pharma&#39;s resubmitted NDA for YOSPRALA; shares up 16% premarket\" data-tweet=\"$ARLZ-OLD - FDA accepts Aralez Pharma&#39;s resubmitted NDA for YOSPRALA; shares up 16% premarket https://seekingalpha.com/news/3169689-fda-accepts-aralez-pharmas-resubmitted-nda-for-yosprala-shares-up-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3169689-fda-accepts-aralez-pharmas-resubmitted-nda-for-yosprala-shares-up-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169686\" data-ts=\"1459168770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169686-gamestopminus-7-weak-guidance-creates-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop -7% as weak guidance creates concerns</a></h4><ul> <li>Sterne Agee CRT warns on GameStop (NYSE:<a href=\"https://seekingalpha.com/symbol/GME\" title=\"GameStop Corp.\">GME</a>) in a <a href=\"http://www.streetinsider.com/Analyst+Comments/Gamestop+%28GME%29+Guidance+Still+Too+High+-+Stern+Agee+CRT/11450824.html\" target=\"_blank\">new note</a> to investors.</li> <li>The investment firm thinks the company's guidance for flat growth in the pre-owned games business is too aggressive. A single-digit decline sounds more likely to analyst Arvind Bhatia.</li> <li>The question mark over preowned growth is somewhat critical with the category accounting for 38% of gross profit last year for GameStop.</li> <li>GME <font color=\"red\">-6.51%</font> premarket to $28.30 after posting results last Thursday post-close. The most notable item from the report was the soft FQ1 guidance issued (-4% to -7%).</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169523-gamestop-beats-0_15-misses-revenue\" target=\"_blank\">GameStop beats by $0.15, misses on revenue</a> (March 24)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169534-gamestop-falls-mixed-results-soft-guidance\" target=\"_blank\">GameStop falls after mixed results, soft guidance</a> (March 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3169686\" data-linked=\"GameStop -7% as weak guidance creates concerns\" data-tweet=\"$GME - GameStop -7% as weak guidance creates concerns https://seekingalpha.com/news/3169686-gamestopminus-7-weak-guidance-creates-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3169686-gamestopminus-7-weak-guidance-creates-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169667\" data-ts=\"1459168190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169667-alder-bios-migraine-candidate-ald403-successful-in-mid-stage-study-shares-up-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder Bio&#39;s migraine candidate ALD403 successful in mid-stage study; shares up 9% premarket</a></h4><ul>\n<li>Small cap Alder BioPharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ALDR\" title=\"Alder Biopharmaceuticals Inc.\">ALDR</a>) is up <font color=\"green\">9%</font> premarket on average volume in response to its announcement  of positive top-line results from a Phase 2b clinical trial assessing lead product candidate ALD403 for the treatment or prevention of migraines.</li>\n<li>The randomized, double-blind, placebo-controlled study evaluated a single IV infusion of <a href=\"http://www.alderbio.com/therapeutics/pipeline/\" target=\"_blank\">ALD403 </a>in five treatment arms (10 mg, 30 mg, 100 mg, 300 mg or placebo) of ~120 patients per arm. The primary endpoint was the change in migraine days versus placebo over a 12-week period as determined by a 75% responder rate. Endpoints will also be assessed at week 24 and week 48 (the end of the study).</li>\n<li>The 100 mg and 300 mg cohorts met the primary endpoint, with 31% and 33% of patients, respectively, achieving a 75% reduction in migraine days over 12 weeks compared to 21% for placebo (p&lt;0.05).</li>\n<li>The secondary efficacy endpoint of a reduction in migraine days versus baseline over 12 weeks was also met for the 300 mg, 100 mg and 30 mg doses.</li>\n<li>Results from a Phase 1 study showed that the pharmacokinetics and pharmacodynamics by IV, subcutaneous or intramuscular injection support a once/quarter single injection dosing strategy for ALD403.</li>\n<li>ALD403 is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that plays a key role in the initiation, mediation, transmission and heightened sensitivity to pain experienced in migraine. It is currently in Phase 3 development.</li>\n<li>The company will host a conference call this morning at 8:30 am ET to discuss the results.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169667\" data-linked=\"Alder Bio&#39;s migraine candidate ALD403 successful in mid-stage study; shares up 9% premarket\" data-tweet=\"$ALDR - Alder Bio&#39;s migraine candidate ALD403 successful in mid-stage study; shares up 9% premarket https://seekingalpha.com/news/3169667-alder-bios-migraine-candidate-ald403-successful-in-mid-stage-study-shares-up-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3169667-alder-bios-migraine-candidate-ald403-successful-in-mid-stage-study-shares-up-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169677\" data-ts=\"1459168018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVOGF\" target=\"_blank\">AVOGF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169677-israeli-gas-stocks-plunge-despite-deleks-reassurances-to-adverse-court-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Israeli gas stocks plunge despite Delek&#39;s reassurances to adverse court ruling</a></h4><ul>\n<li>Shares in Israeli gas companies Avner Oil (<a href=\"https://seekingalpha.com/symbol/AVOGF\" title=\"Avner Oil &amp; Gas Ltd\">OTCPK:AVOGF</a>) and Delek Drilling (<a href=\"https://seekingalpha.com/symbol/DKDRF\" title=\"Delek Drilling\">OTC:DKDRF</a>) sink even after partners in Israel\u2019s Leviathan offshore gas field said the <a href=\"https://seekingalpha.com/news/3169620-israels-supreme-court-strikes-government-gas-deal\" target=\"_blank\">high court  ruling</a> that blocked a proposal to regulate the natural gas industry  <a href=\"http://www.bloomberg.com/news/articles/2016-03-28/leviathan-gas-partners-say-high-court-ruling-won-t-derail-plans\" target=\"_blank\">would not derail their development plans</a>.</li>\n<li>Delek Group (<a href=\"https://seekingalpha.com/symbol/DGRLY\" title=\"Delek Group Ltd. ADR\">OTCPK:DGRLY</a>) CEO Assi Bartfeld said in a conference call that the partners would work hard to find the solutions necessary to come to an agreement, a stance that Barclays analyst Tavy Rosner calls \u201coverly optimistic... The partners are unlikely to manage to  secure export contracts without a stability clause in place. Working around that clause could take several  months.\u201d</li>\n<li>Noble Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/NBL\" title=\"Noble Energy, Inc.\">NBL</a>) Chairman David Stover says the court ruling was \u201cdisappointing and represents another risk to Leviathan timing.\u201d</li>\n<li>In the U.S., NBL <font color=\"red\">-4.1%</font> premarket.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169677\" data-linked=\"Israeli gas stocks plunge despite Delek&#39;s reassurances to adverse court ruling\" data-tweet=\"$AVOGF $AVOGF $DKDRF - Israeli gas stocks plunge despite Delek&#39;s reassurances to adverse court ruling https://seekingalpha.com/news/3169677-israeli-gas-stocks-plunge-despite-deleks-reassurances-to-adverse-court-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3169677-israeli-gas-stocks-plunge-despite-deleks-reassurances-to-adverse-court-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169671\" data-ts=\"1459166928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169671-facebook-gets-price-target-boost-evercore-isi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook gets price target boost at Evercore ISI</a></h4><ul>\n<li>It's all about messaging apps, says Evercore, and messaging combining with AI will drive a new way of doing business. Best positioned for this with its combined 1.8B users is Facebook (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FB\" title=\"Facebook\">FB</a>). The team boost the price target to $150 - 33% above Thursday's close.</li>\n<li>via <a href=\"https://twitter.com/thenotablecalls/status/714419621495832576\" target=\"_blank\">Notable Calls</a>\n</li>\n<li>The stock's <font color=\"green\">higher by 0.5%</font> premarket to $113.58.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3072336-whatsapp-joins-billion-users-club\" target=\"_blank\">WhatsApp joins the billion users club</a> (Feb. 2)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169671\" data-linked=\"Facebook gets price target boost at Evercore ISI\" data-tweet=\"$FB - Facebook gets price target boost at Evercore ISI https://seekingalpha.com/news/3169671-facebook-gets-price-target-boost-evercore-isi?source=tweet\" data-url=\"https://seekingalpha.com/news/3169671-facebook-gets-price-target-boost-evercore-isi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169666\" data-ts=\"1459166553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169666-ad-comm-review-of-acadia-pharmas-nuplazid-tomorrow-shares-up-15-premarket-on-optimism-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm review of ACADIA Pharma&#39;s NUPLAZID tomorrow; shares up 15% premarket on optimism for positive vote</a></h4><ul>\n<li>The FDA's Psychopharmacologic Drugs Advisory Committee <a href=\"http://www.fda.gov/AdvisoryCommittees/Calendar/ucm484121.htm\" target=\"_blank\">meets tomorrow</a> to review ACADIA Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a>) New Drug Application (NDA) seeking clearance of Breakthrough Therapy-tagged NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease.</li>\n<li>Shares are up <font color=\"green\">15%</font> premarket on robust volume in apparent response to encouraging comments in the FDA's briefing document. On page five, paragraph three, it states that it is within the agency's authority to rely on only one positive, well-controlled study to demonstrate efficacy. The company's application is supported by a single Phase 3 study (ACP-103-020) that successfully showed a statistically valid treatment benefit. It submitted the results from three other trials, but none met the primary endpoint. Normally, the agency requires more than one trial to prove efficacy.</li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM492446.pdf\" target=\"_blank\">Draft questions</a></li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM492452.pdf\" target=\"_blank\">FDA briefing doc</a></li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM492453.pdf\" target=\"_blank\">ACADIA briefing doc</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169666\" data-linked=\"Ad Comm review of ACADIA Pharma&#39;s NUPLAZID tomorrow; shares up 15% premarket on optimism for positive vote\" data-tweet=\"$ACAD - Ad Comm review of ACADIA Pharma&#39;s NUPLAZID tomorrow; shares up 15% premarket on optimism for positive vote https://seekingalpha.com/news/3169666-ad-comm-review-of-acadia-pharmas-nuplazid-tomorrow-shares-up-15-premarket-on-optimism-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3169666-ad-comm-review-of-acadia-pharmas-nuplazid-tomorrow-shares-up-15-premarket-on-optimism-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3169641\" data-ts=\"1459162440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALM\" target=\"_blank\">CALM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3169641-on-cal-maine-foods-fq3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Cal-Maine Foods&#39; FQ3</a></h4><ul>\n<li>Cal-Maine Foods (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CALM\" title=\"Cal-Maine Foods, Inc.\">CALM</a>) reports egg sales dropped 1.9% Y/Y to 277.574M in FQ3.</li>\n<li>Specialty-egg sales accounted for 31% of total revenue, up 410 bps Y/Y.</li>\n<li>Average price +4.3% to $1.568 per dozen.</li>\n<li>Gross margin rate improved 380 bps to 29.5%.</li>\n<li>Operating margin rate grew 260 bps to 19.1%.</li>\n<li>CALM <font color=\"green\">+0.56%</font> premarket.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3169641\" data-linked=\"More on Cal-Maine Foods&#39; FQ3\" data-tweet=\"$CALM - More on Cal-Maine Foods&#39; FQ3 https://seekingalpha.com/news/3169641-on-cal-maine-foods-fq3?source=tweet\" data-url=\"https://seekingalpha.com/news/3169641-on-cal-maine-foods-fq3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":43,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}